First Horizon Advisors Inc. Sells 135 Shares of IQVIA Holdings Inc. (NYSE:IQV)

First Horizon Advisors Inc. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,612 shares of the medical research company’s stock after selling 135 shares during the quarter. First Horizon Advisors Inc.’s holdings in IQVIA were worth $906,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Private Trust Co. NA raised its holdings in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares during the period. Clear Harbor Asset Management LLC increased its holdings in shares of IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after purchasing an additional 50 shares during the last quarter. Pine Valley Investments Ltd Liability Co increased its holdings in shares of IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after purchasing an additional 50 shares during the last quarter. Fortitude Family Office LLC increased its holdings in shares of IQVIA by 2.9% in the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after purchasing an additional 56 shares during the last quarter. Finally, Huntington National Bank increased its holdings in shares of IQVIA by 7.4% in the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after purchasing an additional 56 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Activity

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $194.71 on Tuesday. The business’s fifty day simple moving average is $199.52 and its 200-day simple moving average is $215.96. The company has a market cap of $34.29 billion, a PE ratio of 25.96, a PEG ratio of 1.99 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group reduced their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Stephens started coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Finally, Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.